Many pharmacists agree that the original drug is the original, and the generic is its copy that does not have identical properties of the original.. However, as practice shows, generics are becoming more popular and in demand than the original, due to a more affordable price.. To what extent are they able to replace the original?
Expiration of patents on a number of common drugs is estimated at 150 million. US dollars in the period 2010–2017. This opens up new opportunities for generic manufacturers.
To be on the safe side, all pharmaceutical brands try to protect their manufacturer's rights using all sorts of methods, and the most popular and reliable among the methods is legal copy, which provides patent rights.. This document stipulates a condition according to which the reproduction of medical products using the developed formula of the original may be prohibited for several years. In different countries, this figure is different, and can reach 20 years..
The spread of chronic diseases, the emergence of new diseases and the general aging of the population are the main reasons behind the increasing pressure on government agencies to limit the cost of drugs and reduce health care costs.
The coming years are predicted to be marked by significant growth in the global generic pharmaceutical market.. The reason for this is the expiration of patents for several common drugs, as well as the efforts of a number of government agencies and medical institutions aimed at reducing the cost of drugs.. At the same time, we should expect a shift in the balance of healthcare costs and profits from sales from developed markets towards developing ones, which include the markets of Brazil, India, China, Russia, Turkey and South Korea.. These countries have huge untapped potential.
New study by Frost \u0026 Sullivan (an international consulting company) "
Their goal is to obtain marketing rights and exclusive licenses to manufacture generic versions of popular brands such as LIPITOR, Cozaar and Crestor and others.. Market leaders such as Teva, Sandoz and Mylan are increasingly focusing on biosimilars as operating in this segment provides competitive advantages and the opportunity to generate huge profits through high margins..
At the same time, the growth of the generics market may be limited by more stringent government measures in terms of regulation of the pharmaceutical industry and price caps.. This could lead to lower margins for generic manufacturers.
As competition increases, generics will have to be more careful in choosing product segments and time-to-market..
" “Small and mid-sized companies should focus on products with relatively high margins.”.
Who consumes generics?
In countries where the patent protection system is well developed, consumers can first purchase the original drug, and then, after a certain period of time, a generic drug will appear on the medical product market, which a priori will be even more popular than the brand (due to the lower.
Statistics show that the percentage of generics reaches 95%, in other countries of these data the figure is much lower. For example, in the UK - no more than 50%, in Japan and Germany - 30%, in the USA - less than 15%. All this suggests that the exorbitant price of original drugs for our health care is unbearable.. But that's not the point. There would be good quality generics... Sleta Marina.
nedug. en.
e-news. com. ua.